CJC-1295 + Ipamorelin ("CJC/Ipa")
CJC-1295 + Ipamorelin — the "CJC/Ipa" stack, evidence & status

Class: blend
Synonyms: "CJC/Ipa"
"GHRH + GHRP stack"
GH-secretagogue combination. INCI: none
Overall evidence grade: C
WADA prohibited: yes
WADA note: WADA-prohibited (S2
Last updated: 2026-07-04


## Identity a **combination of two separate peptides** — **CJC-1295** (a GHRH-receptor agonist, #16) and **Ipamorelin** (a GHS-R1a / ghrelin-receptor agonist, #17). Not a single compound. ## Rationale the two act through **two different receptors** — GHRH-R and the ghrelin receptor — and their signals are **complementary**, producing a **greater GH pulse together than either alone** (a long-established GHRH + GHRP synergy in endocrine pharmacology). Neither component meaningfully raises cortisol or prolactin, so the combination is relatively "clean" hormonally. It is the most widely used GH-peptide pairing in functional-medicine and gray-market protocols.

Evidence grades by outcome:
outcome: Synergistic GH release (combination)
grade: C
base: Mechanistic (GHRH + GHRP synergy is established); each component raises GH in humans
effect: Larger GH pulse than either alone (plausible)
caveat: Mechanistically sound, but see below — the specific combo is essentially untested in controlled trials
outcome: The specific CJC-1295 + Ipamorelin combination for any clinical endpoint
grade: F
base: No controlled clinical trial has evaluated it
effect: Not demonstrated
caveat: Zero combination RCT; anti-aging/body-composition claims are extrapolation
outcome: Safety (combination)
base: No dedicated human safety data
effect: Unknown
caveat: Inherits both components' unknowns; GH/IGF-1 elevation theoretical risks; WADA-banned

Legal status:
region: INT
status: See note
note: the status of both components applies — placed in 503A Category 2 (2023), status in flux in 2026, not among the July 23–24 2026 PCAC seven, not FDA-approved; not approved in the EU; WADA-prohibited (S2.2).

Cosmetic claims:

Note: Research / reference — not for sale. No dosing, reconstitution, or administration is published (intentional). A combination, not a single molecule — and the most-marketed GH-peptide stack with the least combination-specific evidence.
Honest note: this is the clearest "popularity ≠ evidence" case in the register — the most-marketed GH stack, yet no controlled trial has ever tested the combination. What is known is the pharmacology of each part (they raise GH), not that the stack delivers the outcomes it is sold for.

Sources: